Patent 8722019 was granted and assigned to biOasis Technologies on May, 2014 by the United States Patent and Trademark Office.
The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.